Research
MAR001 lowered triglycerides in a phase 2b trial
In a phase 2b trial, MAR001 lowered fasting triglycerides at 12 weeks, with larger effects among participants whose starting levels were higher.
Researchers reported that the monoclonal antibody MAR001 reduced fasting triglycerides at 12 weeks in adults with elevated levels. The phase 2b TYDAL-TIMI 78 trial compared 300 mg, 450 mg and 900 mg doses with placebo. ACC reported that 236 adults took part, while Healio said its efficacy analysis included 235 participants. ACC reported placebo-adjusted reductions of 39.1, 40.5 and 45.3 percentage points for the three doses. Healio reported 39.1, 40.9 and 45.5 percentage points, respectively.
Adverse events were reported in 69% of participants assigned MAR001 and 78% assigned placebo, according to both reports. Healio said O’Donoghue reported no cases of pancreatitis or elevated liver enzymes in the MAR001 group. The trial ran for 24 weeks, and Healio reported that a separate phase 2b study in participants with severe hypertriglyceridemia is underway. MAR001 is not approved for commercial use in the United States, Healio reported.
